Tracked deals
9
9 tracked deals across 2019-2022.
Private Equity Firm
Healthcare
BroadOak Capital Partners
Brisbane, California, United States
BroadOak Capital Partners is a life-sciences focused boutique financial institution providing direct investment and investment banking services to companies in research tools and consumables, diagnostics, biopharma services, and adjacent markets.
- Focus Areas
- Research tools & consumables, Diagnostics, Biopharma services
- Website
- broadoak.com
Recent pace
0
0 tracked deals announced in the last 12 months.
Deal mix
Growth capital
4 growth capital · 3 buyout · 2 divestiture
BroadOak Capital Partners Acquisition Volume by Year
Last 3 years
Supporting Data
Recent Transactions
-
September 1, 2022
- Buyer
- Flagship Biosciences, Inc., Ampersand Capital Partners, BroadOak Capital Partners, Research Corporation Technologies
- Target
- Interpace Pharma Solutions (IPS)
- Seller
- Interpace Biosciences
- Industry
- Healthcare Services
- Location
- North Carolina, United States
- Type
- Divestiture
Flagship Biosciences has acquired Interpace Pharma Solutions (IPS), a division of Interpace Biosciences, expanding Flagship's molecular pathology, cytogenetics, genomics and biomarker analytics capabilities. The deal follows a growth equity investment in Flagship from Ampersand Capital Partners, BroadOak Capital Partners, and Research Corporation Technologies and adds a state-of-the-art laboratory in Research Triangle Park, North Carolina to Flagship's service offering.
-
- Buyer
- BroadOak Capital Partners, Investor group of industry veterans (including Derek Hennecke and TJ Higley)
- Target
- Microsize
- Seller
- Lonza
- Industry
- Pharmaceuticals
- Location
- Pennsylvania, United States
- Type
- Divestiture
BroadOak Capital Partners led an investor-backed launch of Microsize after acquiring Lonza’s North American micronization business in Quakertown, Pennsylvania. The newly independent CDMO — operating three facilities and focused on micronization and particle-size control for APIs and excipients — will be run by industry veterans including Chairman Derek Hennecke and CEO TJ Higley to expand US-based API solubility and bioavailability enhancement capabilities.
-
- Buyer
- BroadOak Capital Partners, Research Corporation Technologies (RCT)
- Target
- Biolog, Inc.
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Growth capital
BroadOak Capital Partners and Research Corporation Technologies (RCT) made a growth capital investment in Biolog, Inc., a Hayward, California-based provider of cell-based microbial identification and phenotypic profiling technologies. As part of the recapitalization, Robert Wicke was named CEO and the company will use proceeds to advance its cellular analysis product portfolio and expand commercial adoption across pharmaceutical, academic, biotech and environmental markets.
-
February 10, 2022
- Buyer
- Rockland Immunochemicals, Inc., BroadOak Capital Partners, LLC
- Target
- antibodies-online GmbH
- Industry
- Biotechnology
- Location
- North Rhine-Westphalia, Germany
- Type
- Buyout
Rockland Immunochemicals, a Pennsylvania-based life sciences tools manufacturer, has acquired antibodies-online GmbH, a Germany-based e-commerce marketplace for antibodies and research reagents. BroadOak Capital Partners provided financing to support the transaction, which combines Rockland’s antibody design and manufacturing capabilities with antibodies-online’s e-commerce platform and supplier network to expand capabilities, scale distribution, and strengthen supply-chain stability for research customers worldwide.
-
- Buyer
- BroadOak Capital Partners
- Target
- PhenoVista Biosciences
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Growth capital
PhenoVista Biosciences, a San Diego–based provider of high-content, imaging-based phenotypic assay services, raised growth capital from BroadOak Capital Partners. The funding will be used to accelerate development of complex biological models (e.g., blood–brain barrier, neurodegenerative disease platforms) and expand PhenoVista's assay and data-analysis capabilities.
-
- Buyer
- BroadOak Capital Partners, Research Corporation Technologies, Farragut Capital Partners
- Target
- Particle Dynamics
- Seller
- Edgewater Capital Partners
- Industry
- Healthcare Services
- Location
- Missouri, United States
- Type
- Buyout
Particle Dynamics, a U.S.-based specialist in particle processing and finished-dose manufacturing for pharmaceutical, OTC and nutraceutical customers, was sold by Edgewater Capital Partners to a new investor group led by BroadOak Capital Partners with Research Corporation Technologies and Farragut Capital Partners. The transaction (announced September 29, 2021) creates a new ownership group that aims to accelerate the company’s growth and expand its capabilities at its U.S. GMP, FDA-inspected facilities.
-
- Buyer
- BroadOak Capital Partners
- Target
- KromaTiD, Inc.
- Industry
- Biotechnology
- Location
- Colorado, United States
- Type
- Growth capital
BroadOak Capital Partners provided $2.0 million of growth capital to KromaTiD to accelerate commercialization, support product development (including dGH In-Site and dGH SCREEN) and expand capacity to meet rising demand. KromaTiD, a Longmont, Colorado-based provider of single-cell genomic structural analysis for gene editing and gene therapy applications, will use the funding to grow its services and product offerings to biopharma and research customers.
-
November 19, 2019
- Buyer
- Farragut Capital Partners, BroadOak Capital Partners
- Target
- Particle Dynamics, Inc.
- Seller
- Edgewater Capital Partners
- Industry
- Pharmaceuticals
- Location
- Missouri, United States
- Type
- Growth capital
Farragut Capital Partners led a growth investment in Particle Dynamics, Inc., joined by BroadOak Capital Partners; Particle Dynamics is a portfolio company of Edgewater Capital Partners. The capital will support the company's growth and capability expansion across its particle processing, microencapsulation and finished-dosage manufacturing services operating from FDA‑inspected facilities in St. Louis, Missouri and Seymour, Indiana.
-
November 6, 2019
- Buyer
- InFuse Holdings Inc., BroadOak Capital Partners
- Target
- Horizon Infusions, LLC
- Industry
- Healthcare Services
- Location
- Ohio, United States
- Type
- Buyout
InFuse Holdings Inc., backed by a Series A investment led by BroadOak Capital Partners, has acquired Cincinnati-based Horizon Infusions, founded in 1997. The financing and acquisition position Horizon as a platform for InFuse to expand a network of ambulatory infusion centers across Ohio and the Midwest.
Related Acquisition Pages
Biotechnology Buyers & Acquisitions
4 tracked deals by BroadOak Capital Partners.
Healthcare Services Buyers & Acquisitions
3 tracked deals by BroadOak Capital Partners.
Pharmaceuticals Buyers & Acquisitions
2 tracked deals by BroadOak Capital Partners.
Acquisitions in California
2 tracked deals by BroadOak Capital Partners.
Acquisitions in Missouri
2 tracked deals by BroadOak Capital Partners.
Acquisitions in Colorado
1 tracked deal by BroadOak Capital Partners.
Acquisitions in North Carolina
1 tracked deal by BroadOak Capital Partners.
Selling a company? Get in front of buyers like BroadOak Capital Partners
Turn tracked acquisition activity into an outreach-ready buyer list.